

84. Kendler DL, Marin F, Zerbin CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. *Lancet*. 2018;391:230–240.
85. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. *N Engl J Med*. 2017;377:1417–1427.
86. Lindsay R, Cosman F, Zhou H, et al. (2006). A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide. *Journal of Bone and Mineral Research*, 21(3), 366–373.
87. Díez-Pérez A, Marin F, Eriksen EF, et al. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. *Bone*. 2019;120(3):1–8.
88. Simpson EL, Martyn-St James M, Hamilton J (2020) Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. *Bone* 130:115081
89. Orwoll ES, Scheele WH, Paul S, et al. (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. *J Bone Miner Res* 18:9–17
90. Saag KG, Zanchetta JR, Devogelaer JP, et al. (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. *Arthritis Rheum* 60:3346–3355
91. Kaufman, J. M., Orwoll, E., Goemaere, S. et al. (2005). Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy. *Osteoporosis International*, 16(5), 510–516.
92. Lindsay R, Scheele W, Neer R, et al. (2004). Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. *Archives of Internal Medicine*, 164(18), 2024–2030.
93. Leder B, Z, Tsai J, N., Uihlein, A. V., et al. (2014). Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): A randomized controlled trial. *The Journal of Clinical Endocrinology and Metabolism*, 99(5), 1694–1700.
94. Atkins, G. J., & Findlay, D. M. (2012). Osteocyte regulation of bone mineral: A little give and take. *Osteoporosis International*, 23(8), 2067–2079
95. Ominsky, M. S., Niu, Q. T., Li, C. et al. (2014). Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. *Journal of Bone and Mineral Research*, 29(6), 1424–1430.
96. McClung M, R., Grauer, A., Boonen, S. et al. Bone, H. G. (2014). Romosozumab in postmenopausal women with low bone mineral density. *N Engl J Med* 2014, 370(5), 412–420.
97. Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. *N Engl J Med* 375(16):1532–1543
98. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. *N Engl J Med* 2017; 377:1417.
99. Lewiecki, E. M., Blicharski, T., Goemaere, S. et al. (2018). A phase III randomized placebo controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. *The Journal of Clinical Endocrinology and Metabolism*, 103(9), 3183–3193.
100. McClung MR, Brown JP, Díez-Pérez A et al. (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. *J Bone Miner Res* 33(8):1397–1406
101. Cosman F, Crittenden DB, Ferrari S et al (2018) Romosozumab FRAME Study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. *J Bone Miner Res* 33(8):1407–1416
102. Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. *Lancet* 2017; 390:1585.
103. Leslie WD, Lix LM, Johansson H, et al. (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? *J Bone Mineral Research* 27:1243–1251
104. Fink HA, MacDonald R, Forte ML et al (2019) Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. *Ann Intern Med* 171:37–50
105. Dennison EM, Cooper C, Kanis JA, et al. (2019) Fracture risk following intermission of osteoporosis therapy. *Osteoporos Int* 30:1733–1743
106. Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *JAMA* 296:2927–2938
107. Ravn P, Christensen JO, Baumann M, et al. (1998) Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. *Bone* 22:559–564.
108. Watts NB, Chines A, Olszynski WP, et al. (2008) Fracture risk remains reduced one year after discontinuation of risedronate. *Osteoporos Int* 19:365–372
109. Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). *J Bone Miner Res* 27:243–254
110. Cosman F, Cauley JA, Eastell R, et al. (2014) Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? *J Clin Endocrinol Metab* 99:4546–4554
111. Díez-Pérez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis IOF CSA Inadequate Responders Working Group. *Osteoporos Int*. 2012 Dec;23(12):2769–74.
112. Miller, P. D., Pannaciuoli, N., Brown, J. Pet al. (2016). Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. *The Journal of Clinical Endocrinology and Metabolism*, 101(8), 3163–3170.
113. Cosman, F., Nieves, J. W., & Dempster, D. W. (2017). Treatment sequence matters: Anabolic and antiresorptive therapy for osteoporosis. *Journal of Bone and Mineral Research*, 32(2), 198–202.
114. Geusens, P., Marin, F., Kendler, D. L., et al. (2018). Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: The VERO trial. *Journal of Bone and Mineral Research*, 33(5), 783–794.
115. Leder, B. Z., Tsai, J. N., Uihlein, A. V., et al. (2015). Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomized controlled trial. *Lancet*, 386(9999), 1147–1155.
116. Cosman F, Kendler DL, Langdahl BL, et al. Romosozumab and antiresorptive treatment: the importance of treatment sequence. *Osteoporos Int*. 2022 Jun;33(6):1243–1256.
117. Hui RL, Adams AL, Niu F et al (2017) Predicting adherence and persistence with oral bisphosphonate therapy in an integrated health care delivery system. *J Manag Care Spec Pharm* 23(4):503–512
118. Ross S, Samuels E, Gairy K, et al. A meta-analysis of osteoporotic fracture risk with medication nonadherence. *Value Health*. 2011;14:571–581.